Microglial Precursor Cells for the Treatment of Malignant Neoplasms of the Central Nervous System

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of microglial precursor cells—a specific type of partially differentiated immune cell from the myeloid lineage—for treating malignant tumors (neoplasms) of the central nervous system (CNS), particularly brain tumors like gliomas. The invention involves administering these cells directly to patients, where they invade tumor tissues, trigger anti-tumor immune responses, and reduce tumor size. Key distinctions include the ability to derive these cells from pluripotent stem cells and their effectiveness without genetic modification or additional therapies.

Use CasesContent extracted from patent full text and abstract with AI.

• Direct treatment of malignant brain tumors such as gliomas, astrocytomas, and oligodendrogliomas.
• Potential adjunctive therapy in combination with reduced dosages of conventional chemotherapies for CNS tumors.
• Post-surgical treatments to address residual CNS tumor cells and prevent recurrence.
• Delivery of microglial precursor cells during neurosurgical procedures targeting CNS malignancies.
• Treatment of malignant neoplasms elsewhere in the CNS, such as the spinal cord or cranial nerves.

BenefitsContent extracted from patent full text and abstract with AI.

• Demonstrated reduction of tumor size in animal models by up to 10-fold compared to controls.
• Eliminates or reduces the need for genetic engineering of therapeutic cells.
• Can be derived from embryonic or induced pluripotent stem cells, allowing for scalable production.
• Potentially fewer side effects compared to traditional chemotherapies as the cells themselves provide the therapeutic effect.
• Ability to target infiltrative and otherwise inaccessible tumor cells due to the natural migratory and phagocytic behavior of microglial precursors.
• May stimulate the body's own immune system to attack tumor cells, enhancing anti-tumor immunity.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to microglial precursor cells for use in the treatment of malignant neoplasms of the central nervous system. The present invention further relates to a method of treating malignant neoplasms of the central nervous system comprising administering a pharmaceutically effective amount of microglial precursor cells to a subject in need thereof.